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SUMMARY
In studies of the mechanism of immunity to Bordetella pertussis in a murine respiratory infection
model, we have previously demonstrated that natural infection of immunization with a whole cell
vaccine induces a potent protective immune response, which is mediated by T-helper type-l (Thl)
cells. In contrast an acellular vaccine generates Th2 cells and is associated with delayed bacterial
clearance following respiratory challenge. In the present study we have investigated the apparent
Thl/Th2 cell dichotomy in acquired immunity and have examined the factors that affect their
induction or detection. The cytokine profiles of B. pertussis-specific T cells in immune animals were
determined using antigen-stimulated ex vivo spleen cells or CD4+ T-cell lines and clones
established in the presence of interleukin-2 (IL-2) or IL-4. Antigen-specific T cells derived from
mice immunized with the acellular vaccine were almost exclusively of the Th2 cell type. In contrast,
T-cell lines and clones established following respiratory infection or immunization with the whole cell
vaccine were predominantly of the Thl type. However, a proportion of T cells from convalescent
mice, especially when cultured in the presence of IL-4, secreted IL-4 and IL-5 with or without
detectable IL-2 and interferon-y (IFN-y), suggesting that ThO or Th2 cells were also primed during
natural infection in vivo. Furthermore, when mice were assessed 6 months after infection, spleen
cells produced significant levels of IL-4 and IL-5, which were not evident at 6 weeks. The route of
immunization and the genetic background of the mice were also found to influence the preferential
priming of Thl cells, and this was directly related to the level of protection against respiratory or
intracerebral (i.c.) challenge. Our findings underline the critical role ofCD4+ Thl cells in immunity
to B. pertussis, but also demonstrate that a number of factors in the in vivo priming and in vitro
restimulation can skew the apparent dominance of one Th cell type over another.
INTRODUCTION
CD4+ T cells mediate protective immunity against infectious
pathogens by acting as helper cells for antibody responses and
by mediating cellular immune responses against intracellular
pathogens.' Studies with murine CD4+ T-cell clones have
established a clear assocation between cytokine secretion and
function.2 Type-1 CD4+ T cells (Thl cells) mediate delayed-
type hypersensitivity reactions and stimulate macrophages to
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kill intracellular bacteria and parasites,3 but can also provide
help for IgG2a antibodies that are important in protection
against viral infection.4 Type-2 CD4+ T cells (Th2 cells) are
considered to be the main helper T cells, especially for IgA, IgE
and IgGI antibody responses, and in addition activate
eosinophils against certain extracellular parasites.3'5
Bordetella pertussis, a Gram-negative bacterium that causes
the respiratory disease whooping cough in humans, is a suitable
pathogen to study the relative role ofTh cell subpopulations in
protective immunity in murine models. Intracerebral (i.c.)
challenge of naive mice with B. pertussis has a lethal outcome
and is used as a model for vaccine potency testing.6
Resipiratory challenge results in a disease that has many
characteristics of the infection in children and is considered to
be the most suitable model for a study of immunity.7 Pertussis
appears to be a toxin-mediated disease that primarily affects
infants and young children and can cause death.8 A whole cell
vaccine is effective at preventing severe disease.6'9 However,
because of the high frequency of local adverse reactions and
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rare systemic manifestations of its toxicity, the uptake rate of
this vaccine has often dropped below acceptable levels and in
some countries its use has been discontinued.'0 This has
motivated the development of less reactogenic acellular vaccines
based on various purified B. pertussis components. However,
until recently their protective efficacy has been disappointing. I
Bordetella pertussis has classically been considered to be an
extracellular pathogen, hence it has been assumed that
protection is mediated by humoral immunity, which would be
associated with a Th2 response. It has been considered that
local IgA or IgG transudating into the lungs prevents
colonization by inhibiting bacterial adherence to ciliated
epithelial cells in the lungs or prevents disease by neutralizing
toxins. However, analysis of serum antibody responses in a
clinical trial failed to show a correlation between their levels
and protection." There is now convincing evidence to suggest
that B. pertussis can be taken up and survive within
macrophages in the lungs.'2"13 Consistent with these observa-
tions, we have demonstrated protection in a murine respiratory
model in the absence of a detectable antibody response.'4
Athymic mice failed to clear the infection after respiratory
challenge. However, adoptive transfer of immune spleen cells
or purified CD4+ T cells from convalescent donors into nude
or sublethally irradiated recipient mice conferred a high level of
protection. Analysis of the protective T cells from immune
donors revealed that they secreted interleukin-2 (IL-2) and
interferon-y (IF-y), but not IL-4 or IL-5, a cytokine profile
characteristic of Thl cells. '4"15 B. pertussis specific CD4 + T
cells from convalescent children (M. Ryan & K. H. G. Mills,
unpublished observations) or adults that had suffered from
whooping cough in childhood also secrete exclusively type 1
cytokines.'6 Furthermore, immunization of mice with a whole
cell vaccine, which induced a high level of protection against
respiratory challenge, appeared to favour the induction of Thl
cells.'5"17 In contrast, immunization with an acellular vaccine,
comprising purified native filamentous haemagglutinin (FHA),
pertactin and chemically detoxified pertussis toxin (PTd),
adsorbed to alum, generates high antibody levels and
predominantly Th2 cells. Mice immunized with this vacine
show a delay in complete clearance of bacteria from the lungs
following challenge.'5
In the present investigation we have extended these findings
using murine T-cell lines, T-cells clones and ex vivo T cells taken
at extended intervals after immunization. Furthermore, we
have examined the effect of immunization route and the genetic
background of the mice on the induction of Th1/Th2 cells and
protection against B. pertussis challenge. Although the data
provide further evidence of the Thl/Th2 dichotomy in acquired
immunity to B. pertussis, the findings also highlight a number
of factors that influence the selective induction and detection of
cytokine-producing T-cell subsets.
MATERIALS AND METHODS
Bacteria and antigens
Killed B. pertussis Wellcome 28 cells were prepared by heating a
bacterial suspension in phosphate-buffered saline (PBS) at 800
for 30 min. Bordetella pertussis Wellcome 28 was grown at 360
under agitation conditions in Stainer-Scholte liquid medium.'4
Purified pertussis toxin (PT), glutaraldehyde and formalin-
treated PT (PTd), a non-mitogenic genetically toxoided
recombinant PT (rPT),'8 FHA and pertactin prepared from
B. pertussis Tohama, were kindly provided by SmithKline
Beecham (Rixensart, Belgium). The whole cell vaccine (WCV)
used was The Third British Reference Preparation for pertussis
vaccine (NIBSC 88/522).
Mouse immunization
BALB/c and CBA mice were bred and maintained under the
guidelines of the Home Office or the Irish Department of
Health. NIH and C57BL/6 mice were obtained from Harlan
Olac Ltd (Blackthorn, UK). Except for mice used in the
intracerebral (i.c.) challenge experiment, which were 4 weeks
old, all other mice were 2-3 months old at the initiation of
experiments. Unless stated otherwise, mice were immunized at
0 and 4 weeks with 2-0 IU of the whole cell vaccine (88/522) or
an acellular vaccine comprising 12 5 ug each ofFHA, pertactin
and PTd adsorbed to alum ( 0mg potassium aluminium
sulphate) per dose. Immunogens were reconstituted at the
appropriate concentration in PBS such that each mouse received
0-3 ml intraperitoneally (i.p.) or 0-2 ml subcutaneously (s.c.).
Bordetella pertussis challenge
Respiratory infection of mice was performed by aerosol
challenge using a modification of the method described by
Sato et al.'9 Bacteria from a 48-hr culture were resuspended in
physiological saline containing 1% casein at a concentration of
2 x 1010 colony-forming units (CFU)/ml. The challenge inocu-
lum was administered to the mice for 12 min using a nebulizer
in a sealed container within a class 3 exhaust protected cabinet.
The course of respiratory infection was followed by performing
CFU counts on individual lung homogenates using Bordet-
Gengou agar plates, as described previously.'4 The limit of
detection was approximately 3CFU/lung. Results are mean
viable B. pertussis counts for individual lungs from four mice
per group per time-point. Challenge by the i.c. route was
performed using B. pertussis strain 18323, as described by
Kendrick et al.20
Generation of B. pertussis specific T-cell lines and clones
T-cell lines were established from spleens of mice 6 weeks after
respiratory challenge or immunizations (at 0 and 4 weeks) with
the whole cell or acellular vaccines. Spleens were removed and a
single-cell suspension prepared in RPMI-1640 medium supple-
mented with 2% normal mouse serum. Cells were cultured at a
concentration of 2 x 106/ml, and stimulated with killed whole
bacteria (106/ml), rPT (0-2 ug/ml), FHA (1 pg/ml) or pertactin
(1 pg/ml) at 37°in a CO2 incubator. After 4 days fresh medium,
antigen-presenting cells (APC; 2 x 106/ml irradiated syngeneic
spleen cells) and either human recombinant (r)IL-2 (5 U/ml) or
murine rIL-4 (0-5 ng/ml) were added. After a further 7 days, the
surviving T cells were cultured at 1 x 105/ml with the specific B.
pertussis antigen and APC (2 x 106/ml irradiated syngeneic
spleen cells), and maintained on an 11-day cycle of antigen and
cytokine stimulation. Cloning of T-cell lines was performed by
limiting dilution after two to three cycles of antigen stimulation
in vitro. T-cell clones were maintained by restimulation with
antigen as described for the T-cell lines. T-cell lines and clones
were tested for antigen specificity and cytokine production at
the end of the feed/starve cycle, 11 days after antigen
stimulation.
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Cytokine assays
Ex vivo spleen cells (2 x 106/ml) or cultured T-cell lines or
clones (1 x 105/ml) and APC (2 x 106/ml) were cultured with
heat-killed B. pertussis cells (106/ml), FHA (5 pg/ml), pertactin
(5 pg/ml) or rPT (0-2 pg/ml) in 200 yd wells of flat-bottomed 96-
well microtitre plates at 370 in a CO2 incubator. Supernatants
were removed 24 hr after the initiation of culture to test for IL-
2, and after 48 hr to test for IFN-y, IL-4, IL-5 and IL-1O. IL-2
was assayed by testing the ability of supernatants to support the
proliferation of the IL-2- or IL-4-dependent CTLL-2 cell line in
the presence of the anti-IL-4 antibody 1 l-B-l 1 (10 g/ml). The
results are expressed as international units (IU) per ml after
reference to the international standard. IFN-y, IL-4, IL-5 and
IL-10 levels were measured by enzyme-linked immunosorbent
assay (ELISA) using commercially available antibodies (Phar-
mingen, San Diego, CA), as described elsewhere.4'14
IgG subtype analysis
The IgG subclass of serum antibodies was determined against
B. pertussis sonicate or purified FHA, PT or pertactin using a
modification of the ELISA previously described.4"4
RESULTS
Cytokine production by spleen cells from immune mice-effect of
immunogen and route of immunization on Thl/Th2 cell induction
In vitro antigen stimulation of spleen cells from mice 6 weeks
after respiratory infection or immunization with the whole cell
vaccine (O and 4 weeks) by the i.p. route produced high levels of
IL-2 and IFN-y, and undetectable levels of IL-4 and IL-5. In
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contrast, spleen cells from mice immunized with an acellular
vaccine, comprising PTd, FHA and pertactin adsorbed to
alum, produced moderate to high levels of IL-5, but
undetectable IL-2 and IFN-y (Fig. 1). IL-4 could not be
detected in the supernatants from antigen-stimulated spleen
cells from any of these mice.
Immunization with the accellular vaccine by the s.c. route
confirmed the selective induction of Th2 cells, with detectable
levels of IL-4 and moderate levels of IL-5, but undetectable IL-
2 and IFN-y. However, spleen cells from mice immunized with
the whole cell vaccine by the s.c. route also produced low to
moderate levels of IL-4 and IL-5, as well as IFN-y and high
levels of IL-2, suggesting the induction of Th2 or ThO cells as
well as Thl cells using this route of immunization (Fig. 1).
An examination of the specificity of the splenic T cells
producing cytokines in vitro revealed that the type-l cytokines,
IL-2 and IFN-y, were predominantly produced in response to in
vitro restimulation with heat-killed bacteria (Fig. 1) or a
formalin-treated bacterial sonicate (data not shown). Although
moderate and low levels of these cytokines were also produced
in response to FHA and PT, respectively, IL-2 and IFN-y were
undetectable following in vitro stimulation with pertactin. In
contrast, spleen cells from mice immunized with the acellular
vacine produced significant levels of type-2 cytokines, especially
IL-5, in response to in vitro stimulation with FHA and PT.
Cytokine production by B. pertussis-specific T-celi lines and
clones established from convalescent or immunized mice
CT4+ T-cell lines were established from mice that had been
immunized with the pertussis whole cell or acellular vaccines or
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Figure 1. Effect of immunogen and route of immunization on the induction of B. pertussis-specific ThI or Th2 cells. Cytokine
production was assessed in the supernatants of spleen cells derived from BALB/c mice 6 weeks after respiratory infection or
immunization (0 and 4 weeks) with the whole cell vaccine (WCV) or acellular vaccine (ACV) by the i.p. or s.c. routes. Spleen cells were
cultured with heat-killed B. pertussis, FHA, rPT, or pertactin, and IL-2 estimated after 24hr and IL-4, IL-5 and IFN-y after 72 hr.
Results are means of assays from four individual mice performed in triplicate.
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had recovered from respiratory infection by stimulating spleen
cells in vitro with either killed whole bacteria or purified FHA,
rPT or pertactin. Because it has been suggested that the in vitro
restimulation protocol, in particular the choice of exogenous
cytokine, can select for Thl or Th2 cell types, we used two
experimental approaches in which either IL-2 or IL-4 was
added to the cultured T cells. The T-cell lines were periodically
tested for cytokine production by testing supernatants follow-
ing stimulation with specific antigen and irradiated APC; the
results are summarized in Table 1.
T-cell lines specific for FHA, PT, pertactin and other
unidentified B. pertussis antigens were successfully established
from convalescent mice. T-cell lines established in the presence
of IL-2 all produced significant levels of IFN-y, and a
proportion also produced IL-4. In contrast, when IL-4 was
added to the cultures, all except one produced IL-4, with only
four out of the nine producing detectable IFN-y.
It proved more difficult to establish T-cell lines from mice
immunized with the whole cell vaccine. Nevertheless, T-cell
lines were successfully generated by stimulation in vitro with
killed bacteria and rPT, but not with pertactin or FHA. All
of the lines established by stimulation with whole bacteria
by either protocol secreted IFN-y, but not IL-4 (ThI), whereas
T-cell lines specific for PT secreted IL4 and low or
undetectable IFN-y (ThO/Th2).
T-cell lines specific for FHA, PT and pertactin were
successfully generated from mice immunized with the acellular
vaccine and these T-cell lines were more readily established
when IL-4 was added to the cultures. In agreement with the
predominant Th2 type responses detected using ex vivo spleen
cells, all of the T-cell lines from mice immunized with the
acellular vaccine produced significant levels of IL4 (Table 1)
and IL-5 (data not shown), but only one produced detectable
IFN-y.
A number of T-cell clones was generated from convalescent
mice or mice immunized with the acellular vaccine. These were
established from the T-cell lines described in Table 1 and from
bulk cultures of spleen cells from other groups of immune mice
stimulated in vitro with pertactin or rPT. Consistent with the
observations from the ex vivo T cells, B. pertussis-specific
CD4+ T cells generated from convalescent mice were
predominantly, but not exclusively, type 1, whereas T-cell
clones derived from mice immunized with acellular vaccine
were all of the Th2 cell type (Table 2). The clonal analysis also
demonstrated that the heterogeneous cytokine profile observed
in certain cases with polyclonal T-cells lines categorized as ThO
Table 1. Cytokine production by B. pertussis-specific T-cell lines from infected or immunized mice established in the presence of IL-2 or IL-4
IL-2 restimulation IL-4 restimulation
In vivo In vitro IFN-y IL-4 IFN-y IL-4
priming antigen Line no. (ng/ml) (pg/ml) Th type Line no. (ng/ml) (pg/ml) Th type
Inf BP IA 78 < 50 1 lB 38 < 50 1
BP 2A 38 < 50 1 2B 16 623 0
BP 3A 51 < 50 1 3B 45 294 0
Petactin 4A 7 < 50 1 4B < 0 5 607 2
Pertactin 5A 10 < 50 1 5B < 0-5 1000 2
PT 6A 3 202 0 6B 2 501 0
PT 7A 17 290 0 7B <0 5 450 2
FHA 8A 3 640 0 8B <0-5 1083 2
FHA 9A 2 92 0 9B <0-5 1466 2
WCV BP 1OA 28 <05 1 lOB 49 <50 1
BP 11A 70 <0 5 1 liB 8 < 50 1
Pertactin 12A < 0 5 < 50 * 12B < 0-5 < 50 *
Pertactin 13A < 0-5 < 50 * 13B < 0 5 < 50 *
PT 14A 5 1000 0 14B < 0-5 < 50 *
PT 15A < 0 5 264 2 15B < 0 5 < 50 *
FHA 16A < 0-5 < 50 * 16B < 0-5 < 50 *
FHA 17A <0-5 < 50 * 17B <0-5 < 50 *
ACV BP 18A <0-5 221 2 18B 4 275 0
BP 19A <0-5 <50 * 19B <0-5 <50 *
Pertactin 20A < 0-5 > 2000 2 20B < 0-5 > 2000 2
Pertactin 21A < 0-5 < 50 * 21B < 0-5 587 2
PT 22A < 0-5 < 50 * 22B <0-5 450 2
PT 23A <0-5 <5 * 23B < 0-5 <50 *
FHA 24A < 0-5 446 2 24B < 0-5 403 2
FHA 25A < 0-5 505 2 25B < 0-5 > 2000 2
T-cell lines were established from mice following respiratory infection (Inf) or immunization with the whole cell vaccine (WCV) or the acellular
vaccine (ACV) by stimulating spleen cells with heat-killed B. pertussis (BP) or soluble B. pertussis antigens in the presence of IL-2 or IL4. Results are
mean cytokine levels from triplicate assays performed at least twice. T-cell lines were arbitrarily classified into cell types as follows: Thl
(IFN-y > lOng/ml and IL4 < l00pg/ml), Th2 (IFN-y < l-Ong/ml and IL-4 > lOOpg/ml) or ThO (IFN-y > l-Ong/ml and IL-4 > l0Opg/ml).
* T-cell lines which produced very low or undetectable IFN-y or IL-4 or did not survive beyond one to two rounds of antigen stimulation.
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Table 2. Cytokine production by antigen-specific CD4+ T-cell clones established from mice infected with B. pertussis or immunized with a pertussis
acellular vaccine
IFN-y IL-2 IL-4 IL-5 IL-10
In vivo priming Clone Antigen specificity (ng/ml) (lU/ml) (pg/ml) (pg/ml) (pg/ml) Th cell type
Infection IA.3 BP 61 5-4 < 50 < 50 < 50 1
1A.12 BP > 100 2-2 < 50 < 50 < 50 1
1B.2 BP > 100 0 9 <50 <50 <50 1
2A.2 BP > 100 12-7 <50 <50 <50 1
2A.3 BP 26 5-4 80 52 < 50 1
3A.1 BP 46 <0 1 <50 57 <50 1
3A.6 BP > 100 <0 1 < 50 < 50 < 50 1
3B.1 BP > 100 17 52 <50 <50 1
3B.4 BP > 100 3-1 < 50 75 < 50 1
3B.5 BP 05 <01 817 65 <50 2
31.2 Pertactin 33 0-6 167 1287 < 50 0
31.6 Pertactin 43 0 3 60 < 50 < 50 1
Acellular vaccine 20B.2 Pertactin < 0 5 <0 1 > 2000 > 2000 < 50 2
SP.6 PT < 0 5 <0 1 539 682 200 2
SP.7 PT <0 5 <0 1 >2000 178 <50 2
SP.I1 PT <0 5 <0 1 >2000 921 578 2
EP.1 PT <05 01 >2000 137 <50 2
NP.2 PT <0 5 0 1 >2000 221 125 2
Cytokine levels were assayed in supernatants of T-cell clones stimulated with killed B. pertussis or purified antigens in the presence of irradiated
syngeneic APC. Results are the means of triplicate assays performed at least twice.
in Table 1, may reflect a mixture of ThI and Th2 clones.
However, clone 31.2, established from a bulk culture, did
produce IL-2, IL-4, IL-5 and IFN-y, which is more representa-
tive of a ThO profile (Table 2).
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In order to examine the development of the CD4+ T-cell
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Figure 2. Persistence ofThI and Th2 responses 6 months after immunization or infection. Cytokine production was assessed in spleen
cells from mice 6 months after respiratory infection or i.p. immunization (0 and 4 weeks) with the WCV or ACV.
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ThI and Th2 responses detected at 6 weeks (Fig. 1) persisted
over a more prolonged period after in vivo priming, cytokine
production was assessed at intervals after immunization or
challenge using antigen-stimulated spleen cells. The findings in
Fig. 2 demonstrated that B. pertussis-specific CD4+ T-cell
responses were still strong 6 months after respiratory infection
or immunization (O and 4 weeks) with the whole cell vaccine.
Although the responses had waned somewhat, they were still
detectable when tested at 11 and 24 months post-immunization
(data not shown). A persistent type-2 response, with significant
levels of IL-4 and IL-5 (compared with IL-5 only at 6 weeks;
Fig. 1) was also detected 6 months after two immunizations
with acellular vaccine (Fig. 2).
Interestingly, the predominantly Thl response observed
after immunization with the whole cell vaccine appeared to
have switched to a ThO or Thl/Th2 type at 6 months.
Significant levels of IL-4 and IL-5 were detected in super-
natants from spleen cells stimulated with whole killed bacteria,
and to a lesser extent in response to PT, FHA or pertactin. Low
levels of IL-4 and IL-5 were also detected in supernatants of
antigen-stimulated spleen cells taken from mice 6, 11 or 24
months after respiratory infection (Fig. 2 and data not shown).
Nevertheless, the predominant cytokines produced by T cells
from convalescent mice at prolonged intervals after infection
were still IL-2 and IFN-y.
IgG subclass analysis of B. pertussis-specific serum antibodies
correlates with T-cell cytokine profile from immune mice
As T-cell derived cytokine have distinct roles in immuno-
globulin class switching,3 with Thl cytokines associated with
IgG2a and Th2 with IgGl, we investigated the IgG subclasses
of the anti-B. pertussis antibody responses in immune mice.
Following immunization with the acellular vaccine, mice
developed strong antibody responses against PT, pertactin
and FHA and the dominant subclasses were IgGl and IgG3
(Table 3 and data not shown). Immunization with the whole
cell vaccine induced moderate titres of IgG specific for FHA,
PT and pertactin. However, in these mice the ratio of IgGl to
IgG2a was reversed. When examined 6 weeks after infection,
mice had very low levels of specific antibodies; significant levels
were only detected in convalescent mice 8 weeks after challenge,
Table 3. IgG1 and IgG2a serum antibodies to B. pertussis antigens in
mice following immunization or respiratory infection
IgGI: IgG2a specific for
In vivo priming FHA Pertactin PT
Respiratory infection 0-41 0-42 3-3
Whole cell vaccine 0-33 0-74 1 0
Acellular vaccine 1-2 1-57 44
Serum antibody specific for the B. pertussis antigens FHA, pertactin
and PT were tested by ELISA using antibodies specific for mouse IgGI
and IgG2a. Antibodies levels were measured 6 weeks after immuniza-
tion with the whole cell or acellular vaccines, and in convalescent mice 8
weeks after respiratory challenge. The results are expressed as a ratio of
the mean IgG :IgG2a levels for eight mice per group from two
separate experiments.
and the ratios of IgGI: IgG2a specific for FHA and pertactin
were also low. However, IgGl was the dominant subclass of the
anti-PT antibody response in these mice.
Respiratory challenge-protection correlates with a strong Thl
response
In order to establish the correlation between the method of in
vivo priming and the cytokine profile of systemic T cells with the
ability to resist infection, groups of 16-20 immune or control
mice were challenged by aerosol inoculation with viable B.
pertussis, and colony counts were performed on the lungs at
intervals after challenge. Unimmunized control mice showed an
increase in the numbers of bacteria in the lungs in the first 5
days and significant levels were still detectable 14 days after
challenge (Fig. 3). Mice challenged 6 weeks after previous
infection or immunization with the whole cell vaccine by the i.p.
route showed a substantial drop in the numbers of bacteria in
the lungs within 2 days and had undetectable levels 5 days after
challenge. In contrast, clearance was delayed until 14 days after
challenge in mice immunized with the acellular vaccine by the
same route and schedule. Although numbers of bacteria
dropped rapidly after challenge in these mice, low numbers of
bacteria persisted in the lungs 9 days later.
When compared with the i.p. route, immunization with the
whole cell or acellular vaccine by the s.c. route, which was
associated with higher IL-5/IL4 and lower IFN-y levels
(Fig. 1), did not confer as high a level of resistance against
respiratory challenge (Fig. 3). Mice immunized with the whole
cell vaccine by the s.c. route still had detectable bacteria in the
lungs 9 days after challenge, while mice immunized with the
acellular vaccine by this route had not completely cleared the
infection by day 14.
Thl/Th2 responses and protection against i.c. challenge in
different strains of mice
We and others have routinely used BALB/c strain ofmouse for
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Figure 3. Effect of immunogen and route of immunization on
protection against B. pertussis respiratory challenge. BALB/c mice
were aerosol challenged 6 weeks after previous infection (Y) or
immunization (0 and 4 weeks) with the whole cell vaccine i.p. (O) or
s.c. (O) or the acellular vaccines i.p. (0) or s.c. (-). A group of naive
mice (A) was challenged at the same time. Clearance of B. pertussis was
followed by perfoming viable counts on individual lungs at intervals
after challenge. Results are mean (+ SD). CFU estimated for individual
lungs from four mice per group at each time-point.
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Figure 4. IFN-y production by spleen cells from different strains of mice
following immunization with the whole cell vaccine.
the respiratory infection model and for studies on CD4 + T-cell
responses to B. pertussis. 14,16,17 However, NIH mice are
normally used in the Kendrick test, where mice are challenged
i.c. with B. pertussis to determine the potency of pertussis
vaccines.6'20 Here we tested the correlation between Th cell
responses and protection against i.c. challenge induced by the
whole cell vaccine in four mouse strains with different genetic
backgrounds.
Spleen cells from BALB/c (H-2d), CBA (H-2k), NIH (H-2q)
and C57BL/6 (H-2b) mice that had been immunized with the
whole cell vaccine were tested for cytokine production
stimulation with B. pertussis antigens in vitro. Spleen cells
from all four strains of mice produced moderate to high levels
ofIFN-y and IL-2 in response to killed bacteria and lower levels
upon stimulation with PT and FHA, but low or undetectable
levels of IL-4 and IL-5 to any of the antigens tested (Fig. 4 and
Table 4. Influence of genetic background on protection against B.
pertussis i.c. challenge following immunization with the whole cell
vaccine
Whole cell vaccine dose
Mouse strain (IU) Survivors
CBA (H-2k) 1 3/20
0-2 1/19
0-04 0/20
0 0/20
BALB/c (H-2d) 1 9/20
0-2 2/20
0 04 0/20
0 0/20
NIH (H-2q) 1 18/20
0-2 9/20
0-04 2/20
0 0/20
C57BL/6 (H-2b) 1 18/20
0-2 10/18
0-04 3/20
0 0/20
Groups of mice were immunized with graded doses of the pertussis
whole cell vaccine and challenged i.c. with B. pertussis 2 weeks later.
Results are expressed as the number of animals surviving 14 days after
challenge out of the total number challenged in that group.
data not shown). Significantly higher concentrations of IFN-y
were secreted by spleen cells from NIH and C57BL/6 compared
with CBA and BALB/c mice (Fig. 4). This was also observed
for spleen cells from convalescent mice (data not shown).
Groups of 4-week-old BALB/c, CBA, NIH and C57BL/6
mice were immunized once by the i.p. route with graded doses
of the whole cell vaccine, and challenged i.c. with live B.
pertussis 2 weeks later. The numbers of mice surviving from the
total challenged are shown in Table 4. There were no survivors
among the groups of 20 unimmunized control mice from all
four strains. The level of protection in the immunized CBA and
BALB/c mice was poor; 3/20 CBA and 9/20 BALB/c
(compared with 18/20 NIH or C57BL/6) mice survived
challenge following immunization with the highest dose
(10 IU) of the whole cell vaccine. Furthermore, 9/20 NIH
and 10/18 C57BL/6 mice immunized with 0-2 IU of the whole
cell vaccine survived the i.c. challenge.
DISCUSSION
It has now been firmly established that Thl cells play an
important role in protection against intracellular pathogens.
Natural infection with viruses and intracellular bacteria
appears to preferentially activate Thl cells.2'4 However,
attempts to induce Thl cells by immunization, especially with
subunit or purified recombinant antigens, have proved more
difficult.2' In this study we demonstrate a dichotomy in the
CD4+ T-cell response following immunization or infection
with B. pertussis, which is directly relevant to protection against
the pathogen in vivo. Protection against respiratory or i.c.
challenge with B. pertussis was found to correlate with the
induction of antigen-specific Thl cells, which in turn was
influenced by a number of factors including the nature of
immunogen, the route of immunization and strain of mice.
Furthermore, the classification of T-cell subsets into Thl, Th2
or ThO on the basis of cytokine secretion was also affected by
the timing of the test post-immunization and the technique
employed to detect the Th cell subpopulations in vitro.
The original description of Thl and Th2 subpopulations of
CD4+ was based on cytokine secretion by murine T-cell
clones.2 Studies in mice on a number of infectious pathogens,
including Leishmania3 and poliovirus,4 have successfully
employed T-cell cloning techniques to define distinct Thl and
Th2 responses and their association with protection against or
susceptibility to the infection. A number of other techniques,
including quantitative polymerase chain reaction (PCR) for
cytokine mRNA, intracellular staining with anti-cytokine
antibodies and cytokine quantification in supernatants from
antigen or polyclonally activated spleen, lymph node or
peripheral blood lymphocytes have also been used to define
Thl, Th2 or ThO responses. However, these approaches have
often indicated heterogeneous mixtures of Thl and Th2 cell
types. Although the generation of antigen-specific T-cell clones
may overcome this ambiguity, as demonstrated in this and
other studies,22 culture of T cells, especially in the presence of
exogenous cytokines, can alter the pattern of cytokines secreted
and may select for specific cell types.
Regardless of the read-out system employed (ex vivo spleen
cells or T-cell lines and clones), immunization with B. pertussis
components in alum resulted in a clear Th2-type response. In
contrast, analysis of B. pertussis-specific spleen cells 6 weeks
©- 1996 Blackwell Science Ltd, Immunology, 87, 372-380
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after respiratory infection or immunization with the whole cell
vaccine suggested a clear type 1 response. Furthermore, anti-
FHA and anti-pertactin serum IgG subclass analysis revealed
that the dominant Th2 and Thl responses correlated closely
with high or low ratios of IgGl to IgG2a, respectively.
However, cytokine production by T-cell lines and clones
established from convalescent mice allowed the detection of
Th2 and ThO cell types in addition to the dominant ThI
population. While the majority of T-cell lines and clones
produced IFN-y and IL-2, without detectable IL-4 or IL-5, a
minority produced IL-4 and IL-5 or all four cytokines tested. T-
cell lines with ThO or Th2 cytokine profiles were particularly
evident following the addition of exogenous IL-4 to the
cultures. It has recently been demonstrated that regulatory
cytokines can selectively promote the development of Thl or
Th2 cells.22 In our study, the addition ofexogenous IL-4 in vitro
may have inhibited IFN-y-producing cells and stimulated IL-4-
producing cells, thus allowing the expansion of the Th2
subpopulation. In contrast, the production of high levels of
IL-2 and IFN-y, either in bulk spleen cell cultures or the T-cell
lines stimulated in the presence of IL-2, may inhibit prolifera-
tion and cytokine secretion by Th2 cells that may be present,
thus allowing the selective expansion of the Th I subpopulation.
Therefore an apparent dominance of Thl cells defined on the
basis of cytokines secreted by antigen-stimulated spleen cells
may not permit the detection of a minority of Th2 or ThO cells
within these polyclonal populations ex vivo. This is consistent
with the recent suggestion that the classification of T-cell
subsets into distinct Thl or Th2 cell types based on arbitrary
parameters may be an oversimplification of the situation in
vivo.23 Indeed the study at intervals after in vivo priming
suggested that Th2 or ThO cells could be detected by testing
cytokine production by ex vivo spleen cells. In contrast to the
dominant Thl response at 6 weeks, low levels of IL-4 and IL-5,
as well as moderate to high levels of IL-2 and IFN-y, were
detected from antigen-stimulated spleen cells at 6, 11 and 24
months after respiratory infection or immunization with the
whole cell vaccine. The failure to detect type 2 cytokines at 6
weeks may reflect an over-dominance of type 1 cytokine
production early in the immune response and a possible greater
persistence of memory Th2 population.
It has been reported previously24 that IL-4 production is
difficult to detect following primary stimulation in vitro, but can
be readily detected following restimulation or in long-term
cultured T cells. Our findings are partly in agreement with this
observation; IL-4 was undetectable in supernatants of antigen-
stimulated spleen cells taken from mice 6 weeks after i.p.
immunization with the acellular vaccine, despite the demon-
stration of high levels of IL-5. In contrast, established T-cell
lines and clones from these mice all secreted high levels of IL-4
and IL-5. However, when mice were examined 6 months after
immunization significant levels of IL-4 were detected in
antigen-stimulated spleen cell supernatants. Taken together
with the demonstration of IL-4 production 6 weeks after s.c.
immunization and 6, 11 and 24 months after i.p. immunization
with the whole cell vaccine, these findings suggest that the
failure to detect IL-4 following a single in vitro stimulation with
antigen may reflect insensitivity of the assays to detect low
levels of the cytokine, or inhibition of its production in the
presence of high levels of IFN-y.
The functional significance of a dominant Thl or Th2 type
response in relation to protective immunity against a patho-
genic organism in vivo is clearly demonstrated in this study. The
rate of B. pertussis clearance following respiratory challenge
closely reflects the profile of T-cell responses detected. Previous
infection or immunization with the whole cell vaccine by the i.p.
route induced strong Thl responses and conferred a high level
of protection against respiratory challenge. In contrast,
immunization approaches, such as the use of purified antigens
with alum or injection by the s.c. route, which enhanced type 2
cytokine production, were associated with delayed clearance
after challenge.
One explanation for the selective induction of Th2 cells by
the acellular vaccine may be provided by the suggestion that the
putative protective antigens FHA, pertactin and PT are
preferential targets for Th2 cells and do not stimulate Thl
cells. Although our findings indicate that these may not be the
immunodominant antigens of B. pertussis for Thl cells, the
results both from T-cell lines and clones did demonstrate the
priming of pertactin-specific Thl cells. Analysis of cytokine
production using spleen cells suggested that PT and FHA may
also be recognized by a minority ofThl cells from convalescent
mice. Furthermore, we have recently demonstrated that further
manipulation of the in vivo priming or the in vitro restimulation
techniques can permit the generation of Thl cells using purified
B. pertussis components (B. P. Mahon, M. Ryan & K. H. G.
Mills, unpublished observations).25
It has been suggested that in vivo priming of Thl or Th2
cells may be influenced by a number of other factors, including
the APC or the cytokine milieu in the lymphoid tissue at the site
of inoculation.22'26 The switch to higher levels of IFN-y and low
or undetectable IL-4 and IL-5 following i.p., compared with
s.c., immunization provides evidence for the involvement of
APC, because macrophages, which are considered to be the
main APC for Th cells,26 are present in high numbers in the
peritoneal cavity. Furthermore, the targeting of particulate and
soluble antigens to phagocytic and non-phagocytic APC
populations provides an alternative explanation for the
selective induction of Thl and Th2 cells by the whole cell and
acellular vaccines, respectively.
In addition to the immunogen, and site of inoculation, this
study also demonstrated that the strain of mice influenced the
cytokine profile of the responding T-cell population and
subsequent protection against bacterial challenge. An exam-
ination of the T-cell responses following immunization with the
whole cell vaccine in four different strains of mice revealed that
NIH and C57BL/6 mice, compared BALB/c or CBA strains,
secreted significantly higher levels of IFN-y and showed
significantly better survival following i.c. challenge. The i.c.
challenge test developed by Kendrick et al.20 is used routinely
to measure pertussis vaccine potency, and the results of
Medical Research Council trials in the 1950s suggested that
potency in this test correlated with vaccine efficacy in humans.6
When taken together with our recent demonstration that
respiratory infection in children results in the preferential
activation of Thl cells and the failure to find a correlation
between protection and serum antibody levels in clinical
trials," these findings suggest that Thl cells may also play a
key role in immunity against whooping cough in humans.
However, it remains to be determined if enhanced survival
following i.c. challenge or relatively earlier complete bacterial
clearance following respiratory challenge of mice with a strong
(t' 1996 Blackwell Science Ltd. Immunology, 87, 372-380
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Thl response will correlate with the prevention of B. pertussis
infection in children. Nevertheless, future strategies for the
development of improved potency acellular vaccines must
consider the induction of Thl cells.
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